일본의 정액 분석 시장 예측(2025-2032년)

KEY FINDINGS

The Japan semen analysis market is predicted to grow with a CAGR of 6.61% over the forecast period 2025-2032. The market was valued at $60.85 million in 2024 and is expected to reach a revenue of $101.79 million by 2032.

The Japan semen analysis market is set to grow, driven by increasing awareness of infertility, advancements in diagnostic technologies, and the expansion of fertility clinics and ART centers.

Rising demand for convenient and private diagnostic solutions, including at-home semen analysis kits, further supports market growth. However, challenges such as sociocultural stigmas, limited awareness of male reproductive health, and high healthcare costs may hinder progress.

MARKET INSIGHTS

A significant percentage of infertility cases in Japan are attributed to male factors, accounting for approximately 24% of cases historically. Infertility treatment among couples is prevalent, with around 18.2% seeking assistance. This reflects the growing need for advanced diagnostic tools and fertility solutions tailored to address male infertility.

Additionally, Japan faces deep-rooted demographic challenges, with the total fertility rate among men declining from 1.92 to 1.17 over recent years. By 2020, the fertility rate for women had also dropped below 1.4 children per woman, highlighting the urgency of addressing reproductive health issues in the nation.

Lifestyle factors such as smoking and diabetes significantly impact male fertility in Japan. An estimated 18.6 million individuals in Japan were tobacco users in 2022, ranking the country as the 10th globally in tobacco consumption.

Smoking has been linked to reduced semen quality, while 13.5% of the population suffers from type 2 diabetes or impaired glucose tolerance, conditions known to adversely affect sperm quality and quantity. These factors highlight the critical need for accessible and effective male fertility diagnostics.

Technological advancements, including AI-driven innovations, are transforming the semen analysis market in Japan. AI-powered tools provide precise assessments of key sperm parameters, such as count, motility, and morphology, offering reliable solutions in both clinical and home-based settings. The adoption of CASA systems and advanced imaging techniques is further enhancing diagnostic accuracy and efficiency.

SEGMENTATION ANALYSIS

The Japan semen analysis market is segmented into diagnostic technique, testing kits and reagents, age group, and end-user. The diagnostic technique category is further classified into microscopic examination, computer-assisted semen analysis (CASA), and other diagnostic techniques.

CASA systems are gaining traction in fertility clinics and laboratories for their ability to deliver automated and consistent analyses. The rising demand for at-home testing kits reflects a shift toward patient-centered solutions, driven by convenience and privacy.

On the other hand, microscopic examination remains a widely used method for semen analysis in clinical settings, valued for its cost-effectiveness and ability to meet fundamental diagnostic needs.

However, advanced technologies, particularly those integrating AI, are increasingly being adopted to address limitations in traditional techniques and to provide standardized results. These innovations align with the growing demand for accurate and accessible diagnostics.

With a high prevalence of male infertility, lifestyle-related health conditions, and demographic challenges, the demand for advanced reproductive health solutions in Japan is expected to rise. Addressing barriers to awareness and accessibility, alongside the continued integration of innovative technologies, positions Japan as a key market for the development of semen analysis and fertility diagnostics.

COMPETITIVE INSIGHTS

Some of the leading players in the Japan semen analysis market include bioMerieux SA, Optoscopia, Ditect Co Ltd, DNA Diagnostics Center, Hamilton Thorne Inc, etc.

Optoscopia is a leading manufacturer of computer-aided semen analysis (CASA) systems, specializing in the integration of optical technology and artificial intelligence (AI) to meticulously examine sperm samples.

The company's flagship products, the SIA Lab and SIA Lab Plus are designed to process semen samples with high accuracy, assessing essential parameters related to sperm quality, including motility, concentration, vitality, morphology, leukocyte presence, and DNA fragmentation. The company operates through 2 primary locations in Spain and Tunisia.

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

• 1.1. STUDY OBJECTIVES
• 1.2. METHODOLOGY
• 1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

• 2.1. MARKET SIZE & ESTIMATES
• 2.2. COUNTRY SNAPSHOT
• 2.3. COUNTRY ANALYSIS
• 2.4. SCOPE OF STUDY
• 2.5. CRISIS SCENARIO ANALYSIS
• 2.6. MAJOR MARKET FINDINGS
  • 2.6.1. INCREASING PREFERENCE FOR HOME SEMEN ANALYSIS KITS DUE TO CONVENIENCE AND PRIVACY
  • 2.6.2. INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING

3. MARKET DYNAMICS

• 3.1. KEY DRIVERS
  • 3.1.1. INCREASING INCIDENCE OF MALE INFERTILITY IN JAPAN
  • 3.1.2. ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES
  • 3.1.3. EXPANSION OF FERTILITY CLINICS AND ART CENTERS
  • 3.1.4. GROWING AWARENESS OF REPRODUCTIVE HEALTH
• 3.2. KEY RESTRAINTS
  • 3.2.1. HIGH COSTS OF ADVANCED DIAGNOSTIC PROCEDURES
  • 3.2.2. SOCIOCULTURAL STIGMAS ASSOCIATED WITH MALE INFERTILITY
  • 3.2.3. INCONSISTENT INSURANCE COVERAGE AND REIMBURSEMENT POLICIES

4. KEY ANALYTICS

• 4.1. PARENT MARKET ANALYSIS
• 4.2. KEY MARKET TRENDS
  • 4.2.1. INCREASING DEMAND FOR CONVENIENT AND PRIVATE HOME-BASED SEMEN TESTING KITS
• 4.3. PESTLE ANALYSIS
  • 4.3.1. POLITICAL
  • 4.3.2. ECONOMICAL
  • 4.3.3. SOCIAL
  • 4.3.4. TECHNOLOGICAL
  • 4.3.5. LEGAL
  • 4.3.6. ENVIRONMENTAL
• 4.4. PORTER'S FIVE FORCES ANALYSIS
  • 4.4.1. BUYERS POWER
  • 4.4.2. SUPPLIERS POWER
  • 4.4.3. SUBSTITUTION
  • 4.4.4. NEW ENTRANTS
  • 4.4.5. INDUSTRY RIVALRY
• 4.5. GROWTH PROSPECT MAPPING
  • 4.5.1. GROWTH PROSPECT MAPPING FOR JAPAN
• 4.6. MARKET MATURITY ANALYSIS
• 4.7. MARKET CONCENTRATION ANALYSIS
• 4.8. VALUE CHAIN ANALYSIS
  • 4.8.1. EQUIPMENT AND REAGENT MANUFACTURERS
  • 4.8.2. DISTRIBUTORS AND SUPPLIERS
  • 4.8.3. SERVICE PROVIDERS
  • 4.8.4. END-USER
• 4.9. KEY BUYING CRITERIA
  • 4.9.1. ACCURACY AND RELIABILITY
  • 4.9.2. EASE OF USE
  • 4.9.3. COST
  • 4.9.4. TURNAROUND TIME
  • 4.9.5. PORTABILITY AND CONVENIENCE
• 4.10. REGULATORY FRAMEWORK

5. MARKET BY DIAGNOSTIC TECHNIQUE

• 5.1. MICROSCOPIC EXAMINATION
  • 5.1.1. MARKET FORECAST FIGURE
  • 5.1.2. SEGMENT ANALYSIS
• 5.2. COMPUTER-ASSISTED SEMEN ANALYSIS (CASA)
  • 5.2.1. MARKET FORECAST FIGURE
  • 5.2.2. SEGMENT ANALYSIS
• 5.3. OTHER DIAGNOSTIC TECHNIQUES
  • 5.3.1. MARKET FORECAST FIGURE
  • 5.3.2. SEGMENT ANALYSIS

6. MARKET BY TESTING KITS AND REAGENTS

• 6.1. TESTING KITS AND CONSUMABLES
  • 6.1.1. MARKET FORECAST FIGURE
  • 6.1.2. SEGMENT ANALYSIS
• 6.2. REAGENTS AND MEDIA
  • 6.2.1. MARKET FORECAST FIGURE
  • 6.2.2. SEGMENT ANALYSIS

7. MARKET BY AGE GROUP

• 7.1. 34 YEARS AND BELOW
  • 7.1.1. MARKET FORECAST FIGURE
  • 7.1.2. SEGMENT ANALYSIS
• 7.2. 35-40 YEARS
  • 7.2.1. MARKET FORECAST FIGURE
  • 7.2.2. SEGMENT ANALYSIS
• 7.3. 41 YEARS AND ABOVE
  • 7.3.1. MARKET FORECAST FIGURE
  • 7.3.2. SEGMENT ANALYSIS

8. MARKET BY END-USER

• 8.1. HOSPITALS
  • 8.1.1. MARKET FORECAST FIGURE
  • 8.1.2. SEGMENT ANALYSIS
• 8.2. FERTILITY CENTERS
  • 8.2.1. MARKET FORECAST FIGURE
  • 8.2.2. SEGMENT ANALYSIS
• 8.3. DIAGNOSTIC LABORATORIES
  • 8.3.1. MARKET FORECAST FIGURE
  • 8.3.2. SEGMENT ANALYSIS
• 8.4. OTHER END-USERS
  • 8.4.1. MARKET FORECAST FIGURE
  • 8.4.2. SEGMENT ANALYSIS

9. COMPETITIVE LANDSCAPE

• 9.1. KEY STRATEGIC DEVELOPMENTS
  • 9.1.1. MERGERS & ACQUISITIONS
  • 9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
  • 9.1.3. PARTNERSHIPS & AGREEMENTS
  • 9.1.4. BUSINESS EXPANSIONS AND DIVESTITURES
• 9.2. COMPANY PROFILES
  • 9.2.1. BIOMERIEUX SA
    • 9.2.1.1. COMPANY OVERVIEW
    • 9.2.1.2. PRODUCTS
    • 9.2.1.3. STRENGTHS & CHALLENGES
  • 9.2.2. COOPER COMPANIES INC
    • 9.2.2.1. COMPANY OVERVIEW
    • 9.2.2.2. PRODUCTS
    • 9.2.2.3. STRENGTHS & CHALLENGES
  • 9.2.3. DITECT CO LTD
    • 9.2.3.1. COMPANY OVERVIEW
    • 9.2.3.2. PRODUCTS
    • 9.2.3.3. STRENGTHS & CHALLENGES
  • 9.2.4. DNA DIAGNOSTICS CENTER
    • 9.2.4.1. COMPANY OVERVIEW
    • 9.2.4.2. PRODUCTS
    • 9.2.4.3. STRENGTHS & CHALLENGES
  • 9.2.5. HAMILTON THORNE INC
    • 9.2.5.1. COMPANY OVERVIEW
    • 9.2.5.2. PRODUCTS
    • 9.2.5.3. STRENGTHS & CHALLENGES
  • 9.2.6. LEJA PRODUCTS BV
    • 9.2.6.1. COMPANY OVERVIEW
    • 9.2.6.2. PRODUCTS
    • 9.2.6.3. STRENGTHS & CHALLENGES
  • 9.2.7. MEDICAL ELECTRONIC SYSTEMS INC
    • 9.2.7.1. COMPANY OVERVIEW
    • 9.2.7.2. PRODUCTS
    • 9.2.7.3. STRENGTHS & CHALLENGES
  • 9.2.8. OPTOSCOPIA
    • 9.2.8.1. COMPANY OVERVIEW
    • 9.2.8.2. PRODUCTS
    • 9.2.8.3. STRENGTHS & CHALLENGES